विवरण
PYLERA® is a medication used for the treatment of Helicobacter pylori (H. pylori) infection, a common cause of stomach ulcers and gastritis. It contains a combination of three active ingredients: bismuth subcitrate potassium, metronidazole, and tetracycline. This combination works synergistically to eradicate H. pylori bacteria and reduce associated symptoms. Treatment with PYLERA® typically involves taking multiple capsules four times a day for a specified duration, as prescribed by a healthcare provider. It is important to follow the treatment regimen as directed and to discuss potential side effects
सारांश
- Helicobacter pylori is a common chronic bacterial infection affecting 50-60% of the global population, with varying prevalence across regions and socioeconomic conditions. Transmission occurs via fecal-oral or gastric-oral routes, often during childhood, leading to chronic gastritis. While most infected individuals remain asymptomatic, H. pylori can contribute to peptic ulcer disease, gastric cancer, ITP, and iron/B12 deficiency anemia.
- Diagnosis involves non-invasive methods like urea breath tests and stool antigen tests, as well as invasive endoscopy with biopsy for rapid urease testing, histology, and culture. However, prior use of PPIs, bismuth, and antibiotics can lead to false negative results. Gastritis is staged using systems like OLGA/OLGIM, correlating with gastric cancer risk.
- Antibiotic resistance, particularly to clarithromycin and levofloxacin, is a growing global concern. Guidelines recommend bismuth-based quadruple therapy as first-line treatment, especially in regions with high clarithromycin resistance. PILERA, a combination capsule containing bismuth, tetracycline, and metronidazole, is an FDA-approved option with proven efficacy.
- Patient compliance and susceptibility of H. pylori strains to antibiotics are crucial factors for successful eradication. PILERA's safety profile is generally good, with common side effects like dyspepsia, diarrhea, and dysgeusia. Treatment should last 10-14 days with full-dose PPIs, avoiding specific substances and alcohol.
- European registry data supports the use of single-capsule bismuth quadruple therapy as both first-line and rescue treatment. The largest study on this method showed exceeding 90% for the patients, and 85% when used as a rescue therapy. Local studies from the Middle East, including Kuwait and Saudi Arabia, show high eradication rates with PILERA.
नमूना प्रमाण पत्र
वक्ताओं के बारे में
Dr. Filippos Georgopoulos
Head of the Gastroenterology Department and Endoscopy, Al Zahra Private Hospital, Dubai
टिप्पणियाँ
टिप्पणियाँ
टिप्पणी करने के लिए आपको लॉगिन होना होगा।